|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FLNA |
Gene summary for FLNA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FLNA | Gene ID | 2316 |
| Gene name | filamin A | |
| Gene Alias | ABP-280 | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P21333 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2316 | FLNA | AEH-subject1 | Human | Endometrium | AEH | 1.82e-02 | -1.46e-01 | -0.3059 |
| 2316 | FLNA | AEH-subject2 | Human | Endometrium | AEH | 6.80e-05 | -1.94e-01 | -0.2525 |
| 2316 | FLNA | AEH-subject4 | Human | Endometrium | AEH | 1.25e-04 | -2.74e-01 | -0.2657 |
| 2316 | FLNA | AEH-subject5 | Human | Endometrium | AEH | 2.89e-16 | -4.67e-01 | -0.2953 |
| 2316 | FLNA | EEC-subject1 | Human | Endometrium | EEC | 6.22e-15 | -3.24e-01 | -0.2682 |
| 2316 | FLNA | EEC-subject3 | Human | Endometrium | EEC | 3.19e-25 | -3.52e-01 | -0.2525 |
| 2316 | FLNA | EEC-subject4 | Human | Endometrium | EEC | 9.63e-07 | -3.21e-01 | -0.2571 |
| 2316 | FLNA | EEC-subject5 | Human | Endometrium | EEC | 7.48e-09 | -3.19e-01 | -0.249 |
| 2316 | FLNA | GSM5276934 | Human | Endometrium | EEC | 2.58e-06 | -3.10e-01 | -0.0913 |
| 2316 | FLNA | GSM5276935 | Human | Endometrium | EEC | 8.11e-05 | -2.95e-01 | -0.123 |
| 2316 | FLNA | GSM5276937 | Human | Endometrium | EEC | 1.38e-02 | -2.59e-01 | -0.0897 |
| 2316 | FLNA | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.50e-21 | 1.36e-02 | -0.1869 |
| 2316 | FLNA | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.09e-16 | -1.34e-01 | -0.1875 |
| 2316 | FLNA | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.36e-22 | -1.39e-01 | -0.1883 |
| 2316 | FLNA | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 6.31e-17 | -1.66e-01 | -0.1934 |
| 2316 | FLNA | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.31e-31 | -2.35e-01 | -0.1917 |
| 2316 | FLNA | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.09e-33 | -2.11e-01 | -0.1916 |
| 2316 | FLNA | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 4.28e-04 | -2.01e-01 | -0.1269 |
| 2316 | FLNA | LZE4T | Human | Esophagus | ESCC | 1.18e-15 | 6.20e-01 | 0.0811 |
| 2316 | FLNA | LZE7T | Human | Esophagus | ESCC | 3.13e-22 | 1.87e+00 | 0.0667 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190303416 | Prostate | BPH | regulation of response to wounding | 51/3107 | 167/18723 | 5.43e-06 | 8.01e-05 | 51 |
| GO:00164828 | Prostate | BPH | cytosolic transport | 51/3107 | 168/18723 | 6.56e-06 | 9.53e-05 | 51 |
| GO:001081118 | Prostate | BPH | positive regulation of cell-substrate adhesion | 40/3107 | 123/18723 | 1.05e-05 | 1.44e-04 | 40 |
| GO:00600093 | Prostate | BPH | Sertoli cell development | 9/3107 | 12/18723 | 1.28e-05 | 1.70e-04 | 9 |
| GO:00511708 | Prostate | BPH | import into nucleus | 48/3107 | 159/18723 | 1.42e-05 | 1.85e-04 | 48 |
| GO:00431239 | Prostate | BPH | positive regulation of I-kappaB kinase/NF-kappaB signaling | 54/3107 | 186/18723 | 1.50e-05 | 1.92e-04 | 54 |
| GO:00018376 | Prostate | BPH | epithelial to mesenchymal transition | 47/3107 | 157/18723 | 2.21e-05 | 2.67e-04 | 47 |
| GO:01501058 | Prostate | BPH | protein localization to cell-cell junction | 12/3107 | 21/18723 | 2.85e-05 | 3.32e-04 | 12 |
| GO:00508087 | Prostate | BPH | synapse organization | 103/3107 | 426/18723 | 3.19e-05 | 3.61e-04 | 103 |
| GO:00066068 | Prostate | BPH | protein import into nucleus | 46/3107 | 155/18723 | 3.42e-05 | 3.82e-04 | 46 |
| GO:00615649 | Prostate | BPH | axon development | 111/3107 | 467/18723 | 3.51e-05 | 3.88e-04 | 111 |
| GO:190002616 | Prostate | BPH | positive regulation of substrate adhesion-dependent cell spreading | 18/3107 | 41/18723 | 3.62e-05 | 3.95e-04 | 18 |
| GO:190303610 | Prostate | BPH | positive regulation of response to wounding | 26/3107 | 72/18723 | 4.93e-05 | 5.11e-04 | 26 |
| GO:00085844 | Prostate | BPH | male gonad development | 42/3107 | 141/18723 | 6.69e-05 | 6.62e-04 | 42 |
| GO:19045917 | Prostate | BPH | positive regulation of protein import | 18/3107 | 43/18723 | 7.79e-05 | 7.50e-04 | 18 |
| GO:00465464 | Prostate | BPH | development of primary male sexual characteristics | 42/3107 | 142/18723 | 8.00e-05 | 7.66e-04 | 42 |
| GO:00466614 | Prostate | BPH | male sex differentiation | 47/3107 | 165/18723 | 8.70e-05 | 8.22e-04 | 47 |
| GO:19028505 | Prostate | BPH | microtubule cytoskeleton organization involved in mitosis | 43/3107 | 147/18723 | 8.78e-05 | 8.27e-04 | 43 |
| GO:19045898 | Prostate | BPH | regulation of protein import | 23/3107 | 63/18723 | 1.09e-04 | 9.95e-04 | 23 |
| GO:00300489 | Prostate | BPH | actin filament-based movement | 38/3107 | 127/18723 | 1.31e-04 | 1.18e-03 | 38 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
| hsa0451015 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
| hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
| hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
| hsa0451016 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
| hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
| hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
| hsa0451024 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
| hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
| hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
| hsa0451034 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
| hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
| hsa0513239 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
| hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
| hsa05132115 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
| hsa05205112 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FLNA | SNV | Missense_Mutation | novel | c.7115N>T | p.Ser2372Leu | p.S2372L | P21333 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| FLNA | SNV | Missense_Mutation | novel | c.5633N>T | p.Gly1878Val | p.G1878V | P21333 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| FLNA | SNV | Missense_Mutation | c.4510N>A | p.Asp1504Asn | p.D1504N | P21333 | protein_coding | tolerated(0.08) | benign(0.033) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| FLNA | SNV | Missense_Mutation | novel | c.1109N>A | p.Phe370Tyr | p.F370Y | P21333 | protein_coding | tolerated(0.08) | benign(0.168) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| FLNA | SNV | Missense_Mutation | rs201093148 | c.1813N>A | p.Asp605Asn | p.D605N | P21333 | protein_coding | tolerated(0.27) | benign(0.021) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FLNA | SNV | Missense_Mutation | c.4711N>C | p.Asp1571His | p.D1571H | P21333 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FLNA | SNV | Missense_Mutation | novel | c.4868G>T | p.Gly1623Val | p.G1623V | P21333 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FLNA | SNV | Missense_Mutation | c.5164A>G | p.Ile1722Val | p.I1722V | P21333 | protein_coding | tolerated(0.14) | benign(0.326) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FLNA | SNV | Missense_Mutation | novel | c.4757A>G | p.Asp1586Gly | p.D1586G | P21333 | protein_coding | tolerated(0.14) | benign(0.282) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| FLNA | SNV | Missense_Mutation | c.7471G>T | p.Ala2491Ser | p.A2491S | P21333 | protein_coding | deleterious(0.04) | benign(0.44) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2316 | FLNA | DRUGGABLE GENOME, TRANSPORTER | PTI-125 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |